New hope for kids with rare arthritis: sarilumab Dose-Finding trial launches

NCT ID NCT02991469

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times

Summary

This study is for children aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that causes joint swelling and fevers. The purpose is to find the best dose of the drug sarilumab, which helps control inflammation. Researchers will monitor how the drug moves through the body, its safety, and how well it reduces disease activity over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Investigational Site Number : 0320004
RECRUITING

San Miguel de Tucumán, Tucumán Province, T4000, Argentina
Investigational Site Number : 0320005
RECRUITING

Buenos Aires, 1023, Argentina
Investigational Site Number : 1240110
RECRUITING

Calgary, Alberta, T3B 6A9, Canada
Investigational Site Number : 2460040
RECRUITING

Helsinki, 00029, Finland
Investigational Site Number : 2500040
RECRUITING

Paris, 75015, France
Investigational Site Number : 2500041
RECRUITING

Bron, 69500, France
Investigational Site Number : 2500042
RECRUITING

Montpellier, 34295, France
Investigational Site Number : 2760060
RECRUITING

Sankt Augustin, 53757, Germany
Investigational Site Number : 2760062
RECRUITING

Hamburg, 22081, Germany
Investigational Site Number : 2760063
COMPLETED

Sendenhorst, 48324, Germany
Investigational Site Number : 2760064
RECRUITING

Berlin, 13125, Germany
Investigational Site Number : 2760065
RECRUITING

Berlin, 13353, Germany
Investigational Site Number : 3000001
RECRUITING

Athens, 115 27, Greece
Investigational Site Number : 3000002
RECRUITING

Thessaloniki, 546 42, Greece
Investigational Site Number : 3720001
RECRUITING

Crumlin, Dublin, D12 N512, Ireland
Investigational Site Number : 3800051
RECRUITING

Genoa, Genova, 16147, Italy
Investigational Site Number : 3800052
RECRUITING

Rome, Roma, 00165, Italy
Investigational Site Number : 3800054
RECRUITING

Milan, Milano, 20122, Italy
Investigational Site Number : 6430001
COMPLETED

Moscow, 115522, Russia
Investigational Site Number : 6430062
COMPLETED

Moscow, 117997, Russia
Investigational Site Number : 6430063
COMPLETED

Moscow, 119991, Russia
Investigational Site Number : 6430065
COMPLETED

Ufa, 450083, Russia
Investigational Site Number : 7240050
RECRUITING

Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain
Investigational Site Number : 7240051
RECRUITING

Valencia, 46026, Spain
Investigational Site Number : 7240053
RECRUITING

Madrid, 28009, Spain
Investigational Site Number : 7240054
RECRUITING

Málaga, 29010, Spain
Investigational Site Number : 7240055
RECRUITING

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240056
RECRUITING

Madrid, 28010, Spain
Investigational Site Number : 8260031
COMPLETED

London, London, City of, WC1N 3JH, United Kingdom
Investigational Site Number : 8260033
COMPLETED

Liverpool, L12 2AP, United Kingdom
Investigational Site Number : 8260034
RECRUITING

Leeds, LS1 3EX, United Kingdom

Conditions

Explore the condition pages connected to this study.

JUVENILE IDIOPATHIC ARTHRITIS